{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"48.4","value":"16.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility.The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor. A change ≥ 20% in the original volume of the tumor was considered to be clinically significant. Evaluable participants required tumor volume assessment at baseline and at week 24.","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks","id":"OG000","title":"Pasireotide LAR"}],"paramType":"NUMBER","populationDescription":"Evaluable participants required tumor volume assessment at baseline and at week 24","reportingStatus":"POSTED","timeFrame":"Baseline up to 24 weeks","title":"Percentage of Participants With Non-functioning Pituitary Adenomas (NFPA) Who Achieve Tumor Volume Reduction of at Least 20% After 24 Weeks (FAS)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}